Pregled bibliografske jedinice broj: 1276071
Classification of patients with HER2+ breast cancer treated by trastuzumab according to risk of illness progression; Croatian nested cross- sectional study
Classification of patients with HER2+ breast cancer treated by trastuzumab according to risk of illness progression; Croatian nested cross- sectional study // CEOC 2016 Book of Abstracts
Opatija, Hrvatska, 2016. str. 52-52 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 1276071 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Classification of patients with HER2+ breast
cancer treated by trastuzumab according to risk of
illness progression; Croatian nested cross-
sectional study
Autori
August, Davor ; Tečić Vuger, Ana ; Pavlović, Mirjana ; Silovski, Tajana ; Bajić, Žarko
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
CEOC 2016 Book of Abstracts
/ - , 2016, 52-52
Skup
12th Central European Oncology Congress A Best of ASCO®
Mjesto i datum
Opatija, Hrvatska, 22.06.2016. - 25.06.2016
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
breast cancer, risk of disease progression
Sažetak
Addition of trastuzumab to adjuvant chemotherapy regimens provides substantial benefit for women with HER2-positive breast cancer, both in terms of disease recurrence and survival. Objective of our study was to classify patients with HER2+ breast cancer treated with trastuzumab according to risk of disease progression, based on their demographic, vital and clinical characteristics at the time of diagnosis. In conclusion, according to our data, overweight early breast cancer patients whose tumors do not express estrogen receptors have the highest risk of disease progression.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Klinika za tumore,
Klinički bolnički centar Zagreb,
Opća bolnica Karlovac
